Rhythm Pharmaceuticals (RYTM) EBIT (2016 - 2026)
Rhythm Pharmaceuticals (RYTM) reported EBIT of -$52.4 million for Q1 2026, down 11.4% year-over-year from -$59.1 million in Q1 2025, and down 11.26% on a QoQ basis from -$47.1 million in Q4 2025.
Rhythm Pharmaceuticals (RYTM) has 11 years of EBIT data on file, last reported at -$52.4 million in Q1 2026.
- Quarterly EBIT fell 11.4% year-over-year to -$52.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$197.4 million (down 14.34% YoY) and the FY2025 annual result came in at -$192.0 million, up 27.68% from the prior year.
- EBIT eased to -$52.4 million in Q1 2026 per RYTM's latest filing, from -$47.1 million in the prior quarter.
- Across five years, EBIT topped out at -$39.3 million in Q3 2022 and bottomed at -$139.9 million in Q1 2024.
- The 5-year median for EBIT is -$45.3 million (2025), against an average of -$51.4 million.
- The widest annual swing landed in 2024, when EBIT sank 166.29%; it then soared 66.4% in 2025.
- Tracing RYTM's EBIT over 5 years: stood at -$42.1 million in 2022, then advanced by 1.99% to -$41.3 million in 2023, then climbed by 0.02% to -$41.3 million in 2024, then retreated by 14.08% to -$47.1 million in 2025, then retreated by 11.26% to -$52.4 million in 2026.
- Per Business Quant, the three latest RYTM EBIT figures stand at -$52.4 million (Q1 2026), -$47.1 million (Q4 2025), and -$52.7 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Rhythm Pharmaceuticals | 6.00 Bn | 5.66 Bn | 52.96 Mn | -52.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -52.36 Mn |
| Dec 31, 2025 | -47.06 Mn |
| Sep 30, 2025 | -52.65 Mn |
| Jun 30, 2025 | -45.30 Mn |
| Mar 31, 2025 | -47.00 Mn |
| Dec 31, 2024 | -41.26 Mn |
| Sep 30, 2024 | -43.89 Mn |
| Jun 30, 2024 | -40.48 Mn |
| Mar 31, 2024 | -139.89 Mn |
| Dec 31, 2023 | -41.27 Mn |
| Sep 30, 2023 | -43.95 Mn |
| Jun 30, 2023 | -46.60 Mn |
| Mar 31, 2023 | -52.53 Mn |
| Dec 31, 2022 | -42.10 Mn |
| Sep 30, 2022 | -39.27 Mn |
| Jun 30, 2022 | -45.10 Mn |
| Mar 31, 2022 | -52.69 Mn |
| Dec 31, 2021 | -50.99 Mn |
| Sep 30, 2021 | -44.24 Mn |
| Jun 30, 2021 | -40.43 Mn |
| Mar 31, 2021 | -34.40 Mn |
| Dec 31, 2020 | -35.07 Mn |
| Sep 30, 2020 | -34.28 Mn |
| Jun 30, 2020 | -31.92 Mn |
| Mar 31, 2020 | -35.30 Mn |
| Dec 31, 2019 | -34.22 Mn |
| Sep 30, 2019 | -37.11 Mn |
| Jun 30, 2019 | -44.15 Mn |
| Mar 31, 2019 | -30.52 Mn |
| Dec 31, 2018 | -27.15 Mn |
| Sep 30, 2018 | -19.24 Mn |
| Jun 30, 2018 | -15.02 Mn |
| Mar 31, 2018 | -17.00 Mn |
| Dec 31, 2017 | -10.98 Mn |
| Sep 30, 2017 | -8.29 Mn |
| Jun 30, 2017 | -6.75 Mn |
| Mar 31, 2017 | -6.39 Mn |
| Dec 31, 2016 | -8.38 Mn |
| Sep 30, 2016 | -6.40 Mn |